Multi-use patient equipment, such as thermometers, has been linked to one of the largest outbreaks of the emerging drug-resistant fungal pathogen Candida auris to-date.
Browsing: Fungal > Candidiasis
Results from the Phase II STRIVE trial demonstrates favorable safety, tolerability and efficacy of the antifungal drug, rezafungin.
To round up 2017, we asked our Expert panel to choose their top papers from the year. Here, you can discover these articles and the reasons why they were chosen.
This study looks at Candida tropicalis, evaluating if radiation used in radiotherapy can cause changes in the virulence potential.
A new study has identified cyclin-dependent kinases as the key regulator of chromatin snares that are essential for neutrophil immune defense.
New drugs with antifungal action need to be developed. Here, the authors investigate the antifungal activity of MOL3, a small molecule that was selected by virtual screening, against Candida spp.
A novel CRISPR–Cas9-based gene drive platform has been developed by researchers and may help us understand some of the genetic networks underlying virulence in fungal pathogen, Candida albicans.
This research article from Future Microbiology investigates the species distribution and antifungal susceptibility profiles of yeast isolates causing invasive infections across Beijing.
In this interview, we speak to Cornelia Lass-Flörl from the Innsbruck Medical University (Austria) who has a special interest in the epidemiology, diagnosis, prevention and therapy of fungal infections.
Public Health England has released updated guidance on Candida auris, as they confirm that over 200 patients have been infected or colonized with the fungus.